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Supplementary information: 
Thiele et al., “A community-driven global reconstruction of human metabolism”. 
Supplementary Note 1: Comparison of information content in five metabolic 
resources 
Information for reaction and gene comparisons was obtained for the following five 
human metabolism resources: Reactome2, HumanCyc3, KEGG4, the 
compartmentalized Edinburgh Human Metabolic Network (compEHMN)5, and Recon 
16 (see Supplementary Table 8). For this analysis, 406 exchange reactions were 
removed from Recon 1 along with 38 reaction duplicates that differed only in their 
tissue annotation7. From KEGG, the pathways of the category ‘Metabolism’ were 
selected. KEGG is not a human specific database and therefore, only those reactions 
that are linked to one or more human genes were selected. From HumanCyc, the two 
signalling pathways (the ‘BMP Signalling Pathway’ and the ‘MAP kinase cascade’) 
were excluded. From Reactome, ten human pathways focused on (normal) metabolic 
processes were selected, excluding, for example, signalling and disease-related 
pathways. All reactions assigned to the selected metabolic pathways were retrieved. 
Black box events from Reactome, representing reactions for which the molecular 
details are unspecified or unknown, were ignored if either the input or output was 
missing. Out-of-date gene and metabolite identifiers were, where possible, transferred 
to their current identifier or otherwise not taken into account in the comparison. 
Syntactically incorrect metabolite identifiers were corrected manually. 
 
Database Format Version Source 
Recon 1 SBML 1 http://bigg.ucsd.edu/ 
compEHMN Excel 2 http://www.ehmn.bioinformatics.ed.ac.uk/ 
HumanCyc Text 15.0 http://biocyc.org/download.shtml 
KEGG KGML 58 ftp://ftp.genome.jp/pub/kegg/ 
Reactome MySQL database 36 http://reactome.org/download/index.html 
Supplementary Table 8: Versions of the databases used in metabolic resource comparisons. Pathway 
Tools8 was used to export the content of HumanCyc into textual flat files. All data were downloaded in 
May 2011. 
 
Entrez Gene identifiers were used to match genes between databases, since it is the 
only gene identifier provided by all five databases. In HumanCyc, the Entrez Gene 
identifier is missing for 605 genes. For 282 of these genes, the Entrez Gene identifier 
could be retrieved via either the Ensembl Gene identifier (181 genes) or the UniProt 
identifier (101 genes). The remaining 323 genes were excluded from the comparison, 
as they could not be linked to an Entrez Gene id. For 82% of these, none of the three 
identifiers were available. The multiple transcript variants in Recon 1 were flattened 
into a single Entrez Gene identifier. For those databases containing complexes (Recon 
1, HumanCyc, and Reactome), the components (genes) of each complex were 
considered separately in the comparison. Only genes linked to a reaction and/or EC 
number were included in the comparison. 
 
For the reaction comparison, where possible, the KEGG Compound identifier was 
used to match metabolites. If the KEGG Compound identifier was missing, 
metabolites had to match on any of the other metabolite identifiers (KEGG Glycan, 
ChEBI9, PubChem Compound10 or CAS (http://www.cas.org)) or on name, in which 
case also the chemical formula was required to match. Reactions were considered to 
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be the same if all substrates and products (excluding water, electrons and protons) 
matched, irrespective of compartmentalization.  
 
The results of the comparison (see Supplementary Tables 9 and 10) indicated that five 
resources agreed only on a relatively small set of enzyme-encoding genes (510) and 
metabolic reactions (199). These differences indicated that extensive evaluation and 
manual curation would be required to build a consensus network for human 
metabolism with uniform content and representation. Additional differences exist in 
the annotation of the contents among those reconstructions, such as insufficient use of 
identifiers and the genetic basis for the reactions included7. 
 
 Total Unique 
1 other 
database 
2 other 
databases 
3 other 
databases 
4 other 
databases 
Recon 1 1490  45 (3%) 90 (6%) 221 (15%) 624 (42%) 510 (34%) 
EHMN 2492 128 (5%) 868 (35%) 355 (14%) 631 (25%) 510 (20%) 
HumanCyc 3209 759 (24%) 954 (30%) 337 (11%) 649 (20%) 510 (16%) 
KEGG 1535  63 (4%) 138 (9%) 272 (18%) 552 (36%) 510 (33%) 
Reactome 1180 144 (12%) 116 (10%) 174 (15%) 236 (20%) 510 (43%) 
Supplementary Table 9: Comparison of enzyme-encoding genes present in five resources describing 
human metabolism. 
 
 Total Unique 
1 other 
databases 
2 other 
databases 
3 other 
databases 
4 other 
databases 
Recon 1 2549 1250 (49%) 485 (19%) 346 (14%) 269 (11%) 199 (8%) 
EHMN 3695 1832 (50%) 913 (25%) 461 (12%) 290 (8%) 199 (5%) 
HumanCyc 1761 905 (51%) 203 (12%) 197 (11%) 257 (15%) 199 (11%) 
KEGG 1622 348 (21%) 479 (30%) 357 (22%) 239 (15%) 199 (12%) 
Reactome 1131 539 (48%) 100 (9%) 172 (15%) 121 (11%) 199 (18%) 
Supplementary Table 10: Comparison of metabolites present in five resources describing human 
metabolism. 
 
Supplementary Note 2: Biomass composition 
A biomass reaction was added to Recon 2 to account for the macromolecular 
synthesis requirement for proteins, DNA, RNA, lipids, and carbohydrates. The 
biomass composition was determined as described by Thiele and Palsson11. The 
information was assembled from literature and tailored towards leukaemia cell lines 
where specific data were available. 
 
The following macromolecular composition was assumed: protein 70.6%, DNA 1.4%, 
RNA 5.8%, carbohydrates 7.1%, lipids 9.7%, others 5.4%12, 13. The main 
carbohydrate was assumed to be glucose-6-phosphate. ‘Others’ includes vitamins, 
small molecules, ions, cofactors, etc. As no further information was found to the 
compounds included in ‘others’, the biomass reaction does not capture their fractional 
contribution. The cellular weight was assumed as 500x10-12 g per cell. The fractional 
contribution of the different metabolites to the macromolecules was estimated using 
the nucleotide and amino acid sequence of the ~20,000 annotated ORFs. The 
fractional contribution of each amino acid was assumed to be L-alanine 7.6%, L-
arginine 5.4%, L-asparagine 4.2%, L-aspartate 5.3%, L-cysteine 0.7%, L-glutamine 
4.9%, L-glutamate 5.8%, L-glycine 8.1%, L-histidine 1.9%, L-isoleucine 4.3%, L-
leucine 8.2%, L-lysine 8.9%, L-methionine 2.3%, L-phenylalanine 3.9%, L-proline 
6.2%, L-serine 5.9%, L-threonine 4.7%, L-tryptophan 0.2%, L-tyrosine 2.4%, and L-
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valine 5.3%. The fraction contribution of each nucleotide triphosphate to RNA was 
assumed to be ATP 29.4%, CTP 21.4%, GTP 19.8%, and UPT 29.3%. The fractional 
contribution of each deoxynucleotide triphosphate to DNA was assumed to be dATP 
28.9%, dCTP 20.7%, dGTP 21.7%, and dTTP 28.7%. The data for lipid contribution 
was obtained from Sheikh et al.14: cholestorol 7%, cardiolipin 4%, 
phosphatidylinositol 8%, phosphatidylcholine 53%, phosphatidylethanolamine 19%, 
phosphatidylglycerol 1%, sphingomyelin 6%, and phosphatidylserine 2%. The 
following energy requirements for translational processes were assumed: 4 ATP per 
peptidyl bond and an average protein length of 333 amino acids. This biomass 
reaction is a coarse grained approximation of metabolic precursors required and was 
tailored for lymphocytes when data was available.  
 
Supplementary Note 3: Identification of missing functions in human metabolism 
The identification of missing functions was carried out for two dead-end metabolites 
(1-pyrroline-2-carboxylate and 5-amino-2-oxopentanoate) as described previously15. 
Briefly, the associated blocked reactions were computed using FVA analysis16. We 
then used the Smiley algorithm17 implemented in the COBRA Toolbox18 to identify 
non-organism specific reactions from the KEGG4 database that could restore flux 
through the blocked reactions by connecting causative dead-end metabolites to the 
network. If no flux restoring reactions were identified from KEGG, an artificial 
transport reaction was added for the causative dead-end metabolite. 20 solutions, 
comprised of as few reactions as possible, were calculated for each blocked reaction. 
We reviewed the literature in order to verify the biological relevance of the proposed 
solution and to generate a plausible hypothesis for gap filling. 
 
Our example concerns the identification of candidate reactions for the dead-end 
metabolites 1-pyrroline-2-carboxylate and 5-amino-2-oxopentanoate. These 
metabolites are produced by the peroxisomal D-proline and D-ornithine oxidases (EC 
1.4.3.3)19, 20, respectively (Fig. A). These two metabolites exist in equilibrium with 
each other through a hydration reaction21, 22. The suggested resolving reaction 
involved conversion of 1-pyrroline-2-carboxylate to L-proline by pyrroline-2-
carboxylate reductase (EC 1.5.1.1). This reaction has been observed in various 
mammals including rat and monkey22 and, although the cellular localization is 
unknown, there is evidence that the conversion could be non-enzymatic22, 23. L-
proline could then be converted to 1-pyrroline-5-carboxylate by L-pipecolate oxidase 
(EC 1.5.3.7), which has been shown to be localized in the peroxisome and to have 
broad substrate specificity24. It is possible that this reaction could also be catalyzed by 
L-proline oxidase (EC 1.5.1.2/EC 1.5.99.8); however, this enzyme has thus far only 
been localized in the cytoplasm and inner mitochondrial membrane25. Transport of 1-
pyrroline-5-carboxylate out of the peroxisome would then allow 1-pyrroline-5-
carboxylate to enter the tricarboxylic acid cycle or urea cycle, in which it plays an 
anaplerotic role as its tautomeric equivalent L-glutamate-5-semialdehyde25. While it 
is important to state that the proposed solution to the two blocked reactions is a 
hypothesis, the results highlight the benefits of a systems approach towards network 
refinement, without which the potential existence of this reaction pathway would not 
be inducible. 
 
Supplementary Note 4: Basic topological properties of Recon 2 
To assess basic topological features of Recon 2, the compound participation for each 
metabolite was calculated. (Compound participation being the count of how many 
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reactions a given metabolite participates.) Similar trends were observed for both 
Recon 2 and Recon 1 (Fig. B, top). The most connected metabolites in Recon 2 are 
H+ (cytosol) (1210 reactions), water (cytosol) (868), Na+ (cytosol) (483), Na+ 
(extracellular) (479), H+ (mitochondrion) (448), and ATP (cytosol) (380). 
Additionally, reaction length (number of reactants per reaction) was also calculated 
(Fig. B, bottom). Very few reactions have many participating reactants, with – as can 
be expected – the artificial biomass reaction containing the greatest number of 
reactants (41). The average number of reactants per reaction is 4.2±2.6, a result that is 
comparable with Recon 1. 
Nature Biotechnology: doi:10.1038/nbt.2488
	   5 
Supplementary Figure 1: Analysis of cell-type distribution of expressed proteins 
 
Supplementary Figure 1: Protein expression data were obtained from the Human Protein Atlas for 65 
cell types26. Top: Subsystem distribution of the proteins (protein numbers are indicated). Almost a 
quarter of these gene products belonged to Recon 2 categories of lipid metabolism. Middle: Heat map 
of hierarchical clustering of tissues and metabolic enzymes, with red and blue indicating presence and 
absence of enzymes, respectively. On average, there were 214±73 proteins expressed per cell-type, 
with the highest number of metabolic proteins (345) present in cells in kidney tubules and the lowest 
number (64) in endometrial stroma cells in post-menopausal uterus. Bottom: Subsystem distribution of 
enzymes in the four categories of proteins that vary in their expression in different cell types. 
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Supplementary Figure 2: Subsystem distribution of the different reaction 
categories 
 
Supplementary Figure 2: Subsystem distribution of the different reaction categories. 
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Supplementary Figure 3: Correlation between the 65 draft cell-type specific 
models 
kidney -­‐cells -­‐in -­‐tubules
duodenum-­‐glandular -­‐cells
small -­‐ intestine-­‐glandular -­‐ce lls
gall -­‐bladder -­‐glandular -­‐ce lls
colon -­‐glandular -­‐cells
adrenal -­‐gland -­‐glandular -­‐cells
stomach -­‐lower-­‐glandular -­‐ce lls
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testis-­‐Leydig -­‐cells
stomach -­‐upper-­‐glandular -­‐cells
pancreas -­‐exocrine -­‐glandular -­‐cells
prostate -­‐glandular -­‐cells
rectum -­‐glandular -­‐ce lls
seminal -­‐vesicle -­‐glandular -­‐ce lls
thyroid -­‐gland -­‐glandular -­‐cells
appendix -­‐glandular -­‐ce lls
uterus-­‐pre-­‐menopause -­‐glandular -­‐cells
breast-­‐glandular -­‐cells
bronchus-­‐respiratory -­‐epithelial -­‐cells
urinary -­‐bladder -­‐urothelial -­‐ce lls
fallopian -­‐tube-­‐glandular -­‐cells
parathyroid -­‐gland -­‐glandular -­‐cells
placenta -­‐trophoblastic -­‐ce lls
uterus-­‐post-­‐menopause -­‐glandular -­‐cells
epididymis -­‐glandular -­‐ce lls
nasopharynx -­‐respiratory -­‐epithelial -­‐cells
salivary -­‐gland -­‐glandular -­‐ce lls
testis-­‐ce lls -­‐in -­‐seminiferus -­‐ducts
lateral -­‐ventricle -­‐neuronal -­‐ce lls
lung -­‐macrophages
cerebellum -­‐Purkinje -­‐cells
cervix -­‐uterine-­‐glandular -­‐cells
hippocampus -­‐neuronal -­‐ce lls
heart-­‐muscle -­‐myocytes
tonsil -­‐squamous -­‐epithelial -­‐cells
bone-­‐marrow -­‐hematopoietic -­‐cells
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lymph -­‐node-­‐non -­‐germinal -­‐center -­‐cells
placenta -­‐decidual -­‐cells
cerebral -­‐cortex -­‐neuronal -­‐cells
cerebellum -­‐cells -­‐ in-­‐granular -­‐ layer
cerebellum -­‐cells -­‐in -­‐molecular -­‐ layer
liver -­‐bile -­‐duct-­‐cells
spleen -­‐cells -­‐ in-­‐red-­‐pulp
tonsil -­‐non-­‐germinal -­‐center -­‐cells
esophagus -­‐squamous -­‐epithelial -­‐ce lls
tonsil -­‐germinal -­‐center -­‐cells
spleen -­‐cells -­‐ in-­‐white -­‐pulp
vulva -­‐anal -­‐skin -­‐epidermal -­‐cells
lung -­‐pneumocytes
skin -­‐epidermal -­‐cells
appendix -­‐lymphoid -­‐tissue
skeletal -­‐muscle -­‐myocytes
oral -­‐mucosa -­‐squamous -­‐epithelial -­‐cells
lymph -­‐node-­‐germinal -­‐center -­‐cells
smooth-­‐muscle -­‐smooth -­‐muscle-­‐ce lls
cerebral -­‐cortex -­‐glial -­‐ce lls
uterus-­‐pre-­‐menopause -­‐cells -­‐ in-­‐endometrial -­‐stroma
vagina -­‐squamous -­‐epithelial -­‐cells
lateral -­‐ventricle -­‐glial -­‐cells
kidney -­‐cells -­‐ in-­‐glomeruli
cervix -­‐uterine-­‐squamous -­‐epithelial -­‐ce lls
ovary -­‐ovarian -­‐stroma-­‐cells
hippocampus -­‐glial -­‐cells
uterus-­‐post-­‐menopause -­‐cells -­‐ in-­‐endometrial -­‐stroma
 
Supplementary Figure 3: Lower triangle: Based on reaction presence/absence. Upper triangle: Based 
on pathway presence/absence. Pearson correlation coefficients were calculated. 
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Supplementary Figure 4: Correlation between the 65 draft cell-type specific 
models 
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Supplementary Figure 4: Lower triangle: Based on gene presence/absence. Upper triangle: Based on 
presence/absence of inborn errors of metabolism. Pearson correlation coefficients were calculated. 
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Supplementary Figure 5: Subsystem distribution in the 65 draft cell-type specific 
metabolic models based on reaction content 
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Supplementary Figure 5: Subsystem distribution in the 65 draft cell-type specific metabolic models 
based on reaction content. 
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Supplementary Figure 6: Analysis of biofluid data 
 
Supplementary Figure 6: Biofluid distribution of the metabolites in Recon 2, as specified in the Human 
Metabolome Database27. The overlap between metabolites found in blood, urine, and cerebrospinal 
fluid (CSF) is shown in the inset. Most of the metabolites detected in CSF and urine were also present 
in blood. Only four metabolites were unique to CSF, being (S)-N-methylsalsolinol, methylcobalamin, 
D-alanine, and S-adenosylmethioninamine. 
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Figure A: Semi-automated gap filling 
 
Figure A: Semi-automated gap filling suggests candidate, missing reactions, currently not included in 
Recon 2. Top: Schematic outline of the computational gap-filling procedure. A minimal number of 
reactions are borrowed from U or T to be added to S to enable flux through a blocked reaction. Bottom: 
The oxidation of both D-proline and D-ornithine is catalyzed by peroxisomal D-amino oxidase (EC 
1.4.3.3) in Recon 2. Gap filling suggests conversion of 1-pyrroline-2-carboxylate to L-proline through 
EC 1.5.1.1 activity, thus, connecting the dead end metabolites (shaded grey). 
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Figure B: Topological properties of Recon 2 compared with Recon 1 
 
Figure B: Topological properties of Recon 2 compared with Recon 1. Top: Number of reactions each 
reactant participates in. Bottom: Number of reactants per reaction. 
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